Aurora Cannabis Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Miguel Martin
- Full Time Employees
- 1,028
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 90B Street SW Edmonton AB Canada T6X 1V8
- IPO Date
- Sep 26, 2007
- Website
- auroramj.com
- Similar Companies
- Business
- Aurora Cannabis Inc. engages in the production, distribution, and sale of cannabis and cannabis-derived products, operating primarily through two business segments: Canadian Cannabis and Plant Propagation. The company manufactures and sells pharmaceutical-grade medical cannabis products, including dried flower, oils, capsules, and topicals under various brands such as MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co., and international brands including Pedanios, Bidiol, IndiMed, and CraftPlant. Aurora also operates a significant plant propagation business through its controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Its product portfolio caters to medical patients and adult consumers, offering a wide range of cannabis forms including pre-rolls, vaporizers, and concentrates. The company distributes its products domestically in Canada and internationally, notably in key medical cannabis markets including Germany, Australia, Poland, and the United Kingdom. Founded in 2006 and headquartered in Edmonton, Alberta, Canada, Aurora Cannabis has evolved into a leading global medical cannabis company with operations and sales in over 25 countries across five continents. The company has undergone major strategic shifts in recent years, focusing on strengthening its global medical cannabis business and improving profitability. Recent major developments include the acquisition of the remaining approximately 90% equity interest in MedReleaf Australia in early 2024, expanding its footprint in the rapidly growing Australian medical cannabis market. Aurora also acquired Canadian craft cannabis producer Thrive Cannabis, which brought in additional premium recreational cannabis brands to its portfolio and bolstered its Canadian recreational market presence. The company's fiscal 2025 performance marked record annual global medical net revenue, with international revenue more than doubling to represent 61% of total medical cannabis net revenue, supported by plant propagation growth and operational efficiency gains. Aurora’s strategic focus emphasizes innovation, high-quality standards, and expanding international medical cannabis sales while maintaining balance sheet discipline and achieving positive adjusted EBITDA across multiple quarters. Aurora operates advanced cultivation and GMP-certified production facilities, including a notable European facility in Leuna, Germany, ensuring consistent supply quality and regulatory compliance. Its product development is driven by research and development efforts aimed at cannabinoid profile optimization and introduction of new formats and formulations to meet diverse patient and consumer needs. The company maintains a vertically integrated model covering cultivation, processing, and distribution through regulated channels. Aurora’s global reach extends through strategic partnerships, direct sales, and pharmacy networks in jurisdictions where medical cannabis is legalized, supporting its mission to advance patient well-being and accessibility of cannabis-based therapies worldwide. In summary, Aurora Cannabis Inc. is a global cannabis company specializing in medical and adult-use cannabis products, plant propagation, and derivative applications. It operates multiple brands across geographic markets, with a recent strategic pivot emphasizing medical cannabis growth internationally, operational efficiency, and premium product innovation. The company has solidified its international footprint through key acquisitions and organic expansion, positioning itself as a major player in the global cannabis industry with a foundation grounded in science, quality, and diversified product offerings.
Company News
Aurora Rejects Curaleaf's Higher Bid, But the Takeover Fight Isn't Over
Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside
Aurora Cannabis Stock Has Soared 25% Since Curaleaf First Made an Offer to Buy Its Business. Here's Why I Think It Can Go Even Higher
Comparing Aurora Cannabis (NASDAQ:ACB) & BeOne Medicines (NASDAQ:ONC)
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease
Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output
Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway
Curaleaf's Higher Aurora Bid Raises the Stakes in Cannabis Consolidation
Aurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hostile Bid
Aurora Cannabis (TSE:ACB) Shares Up 15.6% – Still a Buy?
Aurora Cannabis Sees Unusually High Options Volume (NASDAQ:ACB)
Curaleaf raises Aurora Cannabis offer by 25%
Comparing ProPhase Labs (NASDAQ:PRPH) and Aurora Cannabis (NASDAQ:ACB)
Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.
Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure
Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond
Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts
Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts
$250,000 in These 3 High-Income ETFs Could Pay You ~$2,800 a Month